SEARCH

SEARCH BY CITATION

References

  • 1
    Ghiringhelli F,Menard C,Terme M,Flament C,Taieb J,Chaput N,Puig PE,Novault S,Escudier B,Vivier E,Lecesne A,Robert C, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-{beta}-dependent manner. J Exp Med 2005; 202: 107585.
  • 2
    Ghiringhelli F,Puig PE,Roux S,Parcellier A,Schmitt E,Solary E,Kroemer G,Martin F,Chauffert B,Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-{beta}-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 91929.
  • 3
    Wei S,Kryczek I,Zou L,Daniel B,Cheng P,Mottram P,Curiel T,Lange A,Zou W. Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma. Cancer Res 2005; 65: 50206.
  • 4
    Curiel TJ,Coukos G,Zou L,Alvarez X,Cheng P,Mottram P,Evdemon-Hogan M,Conejo-Garcia JR,Zhang L,Burow M,Zhu Y,Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 9429.
  • 5
    Woo EY,Chu CS,Goletz TJ,Schlienger K,Yeh H,Coukos G,Rubin SC,Kaiser LR,June CH. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 476672.
  • 6
    Liyanage UK,Moore TT,Joo H-G,Tanaka Y,Herrmann V,Doherty G,Drebin JA,Strasberg SM,Eberlein TJ,Goedegebuure PS,Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 275661.
  • 7
    Yang Z-Z,Novak AJ,Stenson MJ,Witzig TE,Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 363946.
  • 8
    Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004; 10: 9001.
  • 9
    Beyer M,Kochanek M,Giese T,Endl E,Weihrauch MR,Knolle PA,Classen S,Schultze JL. In vivo peripheral expansion of naive CD4+CD25 high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 39409.
  • 10
    Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 26374.
  • 11
    Hilchey SP,De A,Rimsza LM,Bankert RB,Bernstein SH. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25-T Cells. J Immunol 2007; 178: 405161.
  • 12
    Yang Z-Z,Novak AJ,Ziesmer SC,Witzig TE,Ansell SM. Attenuation of CD8+ T-Cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 1014552.
  • 13
    Viguier M,Lemaitre F,Verola O,Cho M-S,Gorochov G,Dubertret L,Bachelez H,Kourilsky P,Ferradini L. Foxp3 expressing CD4+CD25 high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 144453.
  • 14
    Shimizu J,Yamazaki S,Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 52118.
  • 15
    Steitz J,Bruck J,Lenz J,Knop J,Tuting T. Depletion of CD25+ CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon {alpha}-induced. CD8+ T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001; 61: 86436.
  • 16
    Dannull J,Su Z,Rizzieri D,Yang BK,Coleman D,Yancey D,Zhang A,Dahm P,Chao N,Gilboa E,Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 362333.
  • 17
    Ko K,Yamazaki S,Nakamura K,Nishioka T,Hirota K,Yamaguchi T,Shimizu J,Nomura T,Chiba T,Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202: 88591.
  • 18
    Yu P,Lee Y,Liu W,Krausz T,Chong A,Schreiber H,Fu Y-X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 77991.
  • 19
    Golgher D,Jones E,Powrie F,Elliott T,Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002; 32: 326775.
  • 20
    Gray CP,Arosio P,Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 2002; 99: 332634.
  • 21
    Gray CP,Arosio P,Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res 2003; 9: 25519.
  • 22
    Sharma S,Yang SC,Zhu L,Reckamp K,Gardner B,Baratelli F,Huang M,Batra RK,Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65: 521120.
  • 23
    Walker MR,Kasprowicz DJ,Gersuk VH,Benard A,Van Landeghen M,Buckner JH,Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003; 112: 143743.
  • 24
    Moseman EA,Liang X,Dawson AJ,Panoskaltsis-Mortari A,Krieg AM,Liu Y-J,Blazar BR,Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 443342.
  • 25
    Ito T,Yang M,Wang Y-H,Lande R,Gregorio J,Perng OA,Qin X-F,Liu Y-J,Gilliet M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204: 10515.
  • 26
    Yang Z-Z,Novak AJ,Ziesmer SC,Witzig TE,Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25- T cells. Blood 2007; 110: 53744.
  • 27
    Mittal S,Marshall NA,Duncan L,Culligan DJ,Barker RN,Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 535970.
  • 28
    Ishida T,Ishii T,Inagaki A,Yano H,Komatsu H,Iida S,Inagaki H,Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 571622.
  • 29
    Lim HW,Broxmeyer HE,Kim CH. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 2006; 177: 84051.
  • 30
    Wang J,Ioan-Facsinay A,van der Voort EI,Huizinga TW,Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 12938.
  • 31
    Gavin MA,Torgerson TR,Houston E,deRoos P,Ho WY,Stray- Pedersen A,Ocheltree EL,Greenberg PD,Ochs HD,Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103: 665964.
  • 32
    Zou W,Machelon V,Coulomb-L'Hermin A,Borvak J,Nome F,Isaeva T,Wei S,Krzysiek R,Durand-Gasselin I,Gordon A,Pustilnik T,Curiel DT, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 133946.
  • 33
    Farinha P,Masoudi H,Skinnider BF,Shumansky K,Spinelli JJ,Gill K,Klasa R,Voss N,Connors JM,Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 216974.
  • 34
    Dave SS,Wright G,Tan B,Rosenwald A,Gascoyne RD,Chan WC,Fisher RI,Braziel RM,Rimsza LM,Grogan TM,Miller TP,LeBlanc M, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 215969.
  • 35
    Glas AM,Kersten MJ,Delahaye LJMJ,Witteveen AT,Kibbelaar RE,Velds A,Wessels LFA,Joosten P,Kerkhoven RM,Bernards R,van Krieken JHJM,Kluin PM, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 3017.
  • 36
    Glas AM,Knoops L,Delahaye L,Kersten MJ,Kibbelaar RE,Wessels LA,van Laar R,van Krieken JHJM,Baars JW,Raemaekers J,Kluin PM,van't Veer LJ, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 3908.
  • 37
    Cerhan JR,Wang S,Maurer MJ,Ansell SM,Geyer SM,Cozen W,Morton LM,Davis S,Severson RK,Rothman N,Lynch CF,Wacholder S, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109: 543946.
  • 38
    Zeiser R,Leveson-Gower DB,Zambricki EA,Kambham N,Beilhack A,Loh J,Hou JZ,Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 45362.
  • 39
    Ghia P,Strola G,Granziero L,Geuna M,Guida G,Sallusto F,Ruffing N,Montagna L,Piccoli P,Chilosi M,Caligaris-Cappio F. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+. CD40L+ T cells by producing. CCL22. Eur J Immunol 2002; 32: 140313.
  • 40
    Ghia P,Transidico P,Veiga JP,Schaniel C,Sallusto F,Matsushima K,Sallan SE,Rolink AG,Mantovani A,Nadler LM,Cardoso AA. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 2001; 98: 53340.
  • 41
    Nakayama T,Hieshima K,Nagakubo D,Sato E,Nakayama M,Kawa K,Yoshie O. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 2004; 78: 166574.
  • 42
    Farina P,Al-Tourah A,Connors JM,Gascoyne R. The architectural pattern of FoxP3+ T cells predicts risk of transformation in patients with follicular lymphoma. Am Soc Hematol Annu Meet 2007; 110: 112a.